3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
27
Phase 3
8
Phase 1
6
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
3
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Triple Negative Breast Neoplasms
1
Neoplasms
1
Malignant Tumor of Pancreas Metastatic to Liver
1
Cholangiocarcinoma
1
Interventions
Carboplatin
7
Gemcitabine
5
130-nm albumin-bound paclitaxel
3
Paclitaxel
2
olaparib
1
eryaspase
1
camrelizumab
1
Injections
1
Erythrocyte Count
1
Epirubicin
1
Doxorubicin
1
Docetaxel
1
Cyclophosphamide
1
Cisplatin
1
Capecitabine
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Triple Negative Breast Neoplasms
×
Albumin-Bound Paclitaxel
×
Clear all
NCT01881230
2019-02-21
tnAcity
Celgene
Phase 2/3
Completed
191 enrolled
22 charts